Speech impairment in parkinson's disease is improved by trancranial application of electromagnetic fields

References

• Adell A., Trullas R., Gelpi I. Time course of changes in serotonin and noradrenaline in rat brain after predictable or unpredictable shock. Brain Research 1988; 459: 54–59
   PubMed Web of Science ®Google Scholar
• Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives of General Psychiatry 1994; 51: 248–251
   PubMed Web of Science ®Google Scholar
• Bawin S. M., Adey W. R. Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields oscillating at low frequency. Proceedings of the National Academy of Sciences, USA 1976; 73: 1999–2003
   PubMed Web of Science ®Google Scholar
• Biary N., Pimental P., Langenberg P. W. A double blind trial of clonazepam in the treatment of parkinsonian dysarthria. Neurology 1988; 38: 255–258
   PubMed Web of Science ®Google Scholar
• Birkmayer W., Riederer P. Die Parkinson Krankheit. Biochemie, Klinik, Therapie. Springer Verlag, Wien 1980
   Google Scholar
• Brady J. P. The pharmacology of stuttering: a critical review. American Journal of Psychiatry 1991; 148: 1309–1316
   PubMed Web of Science ®Google Scholar
• Brunello N., Barabaccia M. L., Chuang D. M., Costa E. Down-regulation of beta-adrenergic receptors following repeated injections of desmethylimipramine. Permissive role of serotonergic neurons. Neuropharmacoogy 1982; 21: 1145–1149
   PubMed Web of Science ®Google Scholar
• Comings D. E. Tourette syndrome and human behavior. Hope Press, Duarte, CA 1990; 18–345
   Google Scholar
• Comings D. E., Comings B. E. A controlled study of Tourette syndrome. American Journal of Human Genetics 1987; 41: 701–741
   PubMedGoogle Scholar
• Costall B., Naylor R. J., Marsden C., Pycock C. J. Serotonergic modulation of the dopamine responses from the nucleus accumbens. Journal of Pharmacy and Pharmacology 1976; 28: 523–526
   PubMed Web of Science ®Google Scholar
• Critchley E. M. R. Speech disorders of parkinsonism: a review. Journal of Neurology Neurosurgery and Psychiatry 1981; 44: 751–758
   PubMed Web of Science ®Google Scholar
• Darley F. L., Aronson A. E., Brown J. R. Motor speech disorders. W.B. Saunders, Philadelphia 1975; 171–197
   Google Scholar
• Davidson D. L. W., Yates C. M., Yates C. M., Mawdsley C., Pullar I. A., Wilson H. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. Journal of Neurology Neurosurgery and Psychiatry 1977; 40: 1136–1141
   PubMed Web of Science ®Google Scholar
• Dray A. Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. Journal of Physiology, (Paris) 1981; 77: 393–403
   PubMedGoogle Scholar
• Durif F., Vidailhet M., Bonnet A. M., Blin J., Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995; 45: 1855–1858
   PubMed Web of Science ®Google Scholar
• Everett G. M., Borcherding J. W. L-dopa: effect on concentration of dopamine, norepinephrine, and serotonin in brains of mice. Science 1970; 168: 849–850
   PubMed Web of Science ®Google Scholar
• Fahn S., Libsch L. R., Cutler R. W. Monoamines in the human neostriatum: Topographic distribution in normals in Parkinson's disease and their role in akinesia, rigidity, chorea and tremor. Journal of Neurological Sciences 1971; 14: 427–455
   PubMed Web of Science ®Google Scholar
• Fontenot M. B., Kaplan J. R., Manuck S. B., Arango V., Mann J. J. Long-term effects of chronic social stress on serotonergic indices in the prefrontal cortex of adult male cynomolgus macaques. Brain Research 1995; 705: 105–108
   PubMed Web of Science ®Google Scholar
• Fuller R. W. Pharmacologic modification of serotonergic function: drugs for the study and treatment of psychiatric and other disorders. Journal of Clinical Psychiatry 1986; 47: 4–8, (suppl 4)
   PubMed Web of Science ®Google Scholar
• Gershanik O. S., Heikkila R. E., Duvoisin R. C. The role of serotonin neurons in the action of L-dopa in an animal model of Parkinsonism. Neurology 1979; 29: 553
   Web of Science ®Google Scholar
• Goldstein J. A. Carbamazepine treatment for stuttering. Journal of Clinical Psychiatry 1987; 48: 39
   PubMedGoogle Scholar
• Hesselink J. M. K. Serotonin, depression and PD. Neurology 1993; 43: 1624–1625
   Google Scholar
• Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427–442
   PubMed Web of Science ®Google Scholar
• Hwang E. C., Van Woert M. H. Antimyoclnic action of clonazepam: the role of serotonin. European Journal of Pharmacology 1979; 60: 31–40
   PubMedGoogle Scholar
• Jaffe R. A., Laszewski B. L., Carr D. B., Phillips R. D. Chronic exposure to a 60-Hz electric field: effects on synaptic transmission and peripheral nerve function in the rat. Bioelectromagnetics 1980; 1: 131–147
   PubMedGoogle Scholar
• Javoy-Agid F., Ruberg M., Taquet H., Bokobza B., Agid Y., Gaspar P., Berger B., N'Guyen-Legros J., Alvarez C., Gray F., Escourolle R., Scatton B., Rouquier L. Biochemical neuropathology of Parkinson's disease. Advances in neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; Vol. 40: 189–198
   Google Scholar
• Jurgens U., Ploog D. On the neural control of mammalian vocalization. Trends in Neurosciences 1981; 4: 135–137
   Google Scholar
• Kienzl E., Riederer P., Jellinger K., Wesemann W. Transitional states of centreal serotonin receptors in Parkinson's disease. Journal of Neural Transmission 1981; 51: 113–122
   PubMed Web of Science ®Google Scholar
• Kiziltan G., Akalin M. A. Stuttering may be a type of action dystonia. Movement Disorders 1996; 11: 278–282
   PubMedGoogle Scholar
• Koller W. C. Dysfluency (stuttering) in extrapyramidal disease. Archives of Neurology 1983; 40: 175–177
   PubMed Web of Science ®Google Scholar
• Kostic V. S., Dijuric B. M., Covickovic-Sternic N., Bumbasirevic L., Nicolic M., Mrsulja B. B. Depression and Parkinson's disease: possible role of serotonergic mechanisms. Journal of Neurology 1987; 234: 94–96
   PubMed Web of Science ®Google Scholar
• Logemann J. A., Fisher H. B., Boshes B., Blonsky E. R. Frequency and occurrence of vocal tract dysfunction in the speech of a large sample of Parkinson patients. Journal of Speech & Hearing Disorders 1978; 43: 47–57
   PubMedGoogle Scholar
• Markstein R. Neurochemical effects of some ergot derivatives: a basis for their antiparkinsonian actions. Journal of Neural Transmission 1981; 51: 39–59
   PubMedGoogle Scholar
• Marsden C. D., Parkes J. D. “On and off” variability and response swings in Parkinson's disease. Research progress in parkinson's disease, F. C. Rose, R. Capildeo. Pitman Medical, Kent 1980; 265–274
   Google Scholar
• Mayeux R., Stern Y., Sano M., Cote L., Williams J. B. W. Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurology 1987; 37: 1130–1134
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Williams J. B. W., Cote L. J. The relationship of serotonin to depression in Parkinson's disease. Movement Disorders 1988; 3: 237–244
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Marek K. L., Price L. H. Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 1992; 42: 1813–1814
   PubMed Web of Science ®Google Scholar
• Meara J. Serotonin and the extrapyramidal system- a neurological perspective. Human Psychopharmacology 1996; 11: S95–S102
   Google Scholar
• Mlcoch A. G. Diagnosis and treatment of parkinsonian dysarthria. Handbook of Parkinson's disease, W. C. Koller. Marcel Dekker, Inc., New York 1987; 181–207
   Google Scholar
• Nieuwenhuys R. Chemoarchitecture of the brain. Springer Verlag, Berlin 1985; 33–41
   Google Scholar
• Pujol J. F. Interactions between serotonin and noradrenaline containing neurons: link between the raphe system and the locus coeruleus. Advances in pharmacological therapeutics, P. Simon. Pergamon Press, Oxford 1979; Vol. 2: 417–429
   Google Scholar
• Riederer P. L-dopa competes with tyrosine and tryptophan for human brain uptake. Nutrition & Metabolism 1980; 2A: 417–423
   Google Scholar
• Sandyk R. Weak magnetic fields as a novel therapeutic modality in Parkinson's disease. International Journal of Neuroscience 1992a; 66: 1–15
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields in the treatment of Parkinson's disease with the “on-off” phenomenon. International Journal of Neuroscience 1992b; 66: 97–106
   PubMed Web of Science ®Google Scholar
• Sandyk R. Magnetic fields in the therapy of Parkinsonism. International Journal of Neuroscience 1992c; 66: 209–235
   PubMed Web of Science ®Google Scholar
• Sandyk R. A drug naive Parkinsonian patient successfully treated with electromagnetic fields. International Journal of Neuroscience 1994a; 79: 99–110
   PubMed Web of Science ®Google Scholar
• Sandyk R. Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkinsonian medications. International Journal of Neuroscience 1994b; 74: 191–201
   PubMedGoogle Scholar
• Sandyk R. Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields. International Journal of Neuroscience 1996; 85: 111–124
   PubMed Web of Science ®Google Scholar
• Sandyk R. Treatment with AC pulsed electromagnetic fields improves the response to levodopa in Parkinson's disease. International Journal of Neuroscience, (in press)
   Web of Science ®Google Scholar
• Sandyk R., Derpapas K. Further observations on the unique efficacy of picotesla magnetic fields in Parkinson's disease. International Journal of Neuroscience 1993; 69: 167–183
   PubMedGoogle Scholar
• Sandyk R., Iacono R. P. Reversal of visual neglect in Parkinson's disease by treatment with picotesla range magnetic fields. International Journal of Neuroscience 1993; 73: 93–107
   PubMedGoogle Scholar
• Sandyk R., Fisher H. Serotonin in involuntary movement disorders. International Journal of Neuroscience 1988; 42: 185–205
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. L-tryptophan supplementation in Parkinson's disease. International Journal of Neuroscience 1989; 45: 215–219
   PubMed Web of Science ®Google Scholar
• Sawada M., Nagatsu T., Nagtsu I., Ito K., Iizuka R., Kondo T., Narabayashi H. Tryptophan hydroxylase activity in the brains of controls and Parkinsonian patients. Journal of Neural Transmission 1985; 62: 107–115
   PubMed Web of Science ®Google Scholar
• Scatton B., Javoy-Agid F., Rouquier L., Dubois B., Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Research 1983; 275: 321–328
   PubMed Web of Science ®Google Scholar
• Scatton B., Dennis T., L'heureux R., Monfort J. C., Duyckaerts C., Javoy-Agid F. Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Research 1986; 380: 181–185
   PubMed Web of Science ®Google Scholar
• Tetrad J. W. Preclinical Parkinson's disease: detection of motor and nonmotor manifestations. Neurology 1991; 41: 69–72, (suppl 2)
   Google Scholar
• Tohgi H., Abe T., Takahashi S., Takahashi J., Hamato H. Alteration in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neuroscience Letters 1993; 159: 135–138
   PubMed Web of Science ®Google Scholar
• Wingate M. E. A standard definition of stuttering. Journal of Speech and Hearing Disorders 1964; 29: 484–489
   PubMedGoogle Scholar